We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Even though European legal constraints on transferring personal data could have profound effects on U.S. drugmakers, few of them have become certified under a U.S.-European Union (E.U.) safe harbor agreement, perhaps because the pact's enforcement provisions are making them uneasy, according to industry experts.
Drugmakers’ consumer education, disease management and patient compliance websites that allow individuals to submit private information can expose manufacturers to FTC enforcement actions if security measures are insufficient, according to an FTC attorney.
After three years of legal challenges that went all the way to the U.S. Supreme Court, Maine on Saturday launched its prescription drug discount plan that uses the state’s buying power under Medicaid to leverage lower prices from manufacturers.
In a move that could bode well for drugmakers’ bottom line, Europe’s highest court yesterday ruled that German drugmaker Bayer AG did not violate European Union (E.U.) trade rules when it restricted shipments of its heart drug Adalat to certain E.U. states that set low drug prices.